Methods and compositions for dosing in adoptive cell therapy

Patent metadata

Field	Value
Publication number	US-11633426-B2
Application number	US-201916667564-A
Country	US
Kind code	B2
Filing date	Oct 29, 2019
Priority date	Oct 20, 2014
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.

First claim

The invention claimed is:

1. A method of treatment, comprising
administering a consecutive dose of T cells expressing a chimeric antigen receptor (CAR) that binds to CD19 to a subject having a hematologic malignancy and having been previously administered a first dose of T cells expressing a CAR that binds to CD19, wherein:
(i) the first dose comprises no more than about 1×10 6 of the cells per kilogram body weight of the subject (cells/kg), no more than about 1×10 8 of the cells, or no more than about 1×10 8 of the cells/m 2 of the subject; and
(ii) the consecutive dose of cells is administered between about 14 days after and about 28 days after initiation of the administration of the first dose of cells.

2. The method of treatment of claim 1 , further comprising administering to the subject the first dose of cells.

3. The method of claim 1 , wherein, at the time of the administration of the consecutive dose:
(i) the serum level in the subject of a factor indicative of cytokine release syndrome (CRS) is no more than about 50 times that in the subject immediately prior to the administration of the first dose; and/or
(ii) the subject does not exhibit grade 3 or higher neurotoxicity;
(iii) a CRS-related outcome or symptom of neurotoxicity in the subject has reached a peak level and begun to decline following the administration of the first dose; or
(iv) the subject does not exhibit a detectable humoral or cell-mediated immune response against the CAR expressed by the cells in the first dose.

4. The method of claim 1 , wherein prior to the administration of the first dose of cells, the subject has not received a dose of cells expressing the CAR expressed by the cells in the first dose.

5. The method of claim 1 , wherein the CAR expressed by the cells in the first dose and the CAR expressed by the cells in the consecutive dose contain the same antigen-binding domain.

6. The method of claim 1 , wherein the CAR expressed by the cells in the consecutive dose is identical to the CAR expressed by the cells in the first dose.

7. The method of claim 1 , wherein:
the first dose comprises cells in an amount sufficient for reduction in burden of the hematologic malignancy in the subject.

8. The method of claim 1 , further comprising:
(i) assessing a factor indicative of disease burden after administration of the first dose of cells and prior to administration of the consecutive dose of cells;
(ii) based on the result of the assessment, determining the consecutive dose of cells to be administered to the subject; and
(iii) (1) if the assessment determines that the subject has morphologic disease, administering to the subject a consecutive dose comprising less than or about the same number of CAR-expressing cells as the number of CAR-expressing cells in the first dose; or
(2) if the assessment determines that the subject has minimal residual disease, administering to the subject a consecutive dose comprising an increased number of CAR-expressing cells as compared to the first dose.

9. The method of claim 1 , wherein:
if at a time just prior to initiation of administration of the consecutive dose of cells, the subject exhibits morphologic disease, the consecutive dose comprises less than or about the same number of CAR-expressing cells as the number of CAR-expressing cells in the first dose.

10. The method of claim 1 , wherein the number of CAR-expressing cells administered in the consecutive dose comprises between about 2×10 6 cells/kg- and about 6×10 6 cells/kg each inclusive.

11. The method of claim 1 , wherein the time between the first dose and the consecutive dose is from about 15 to about 27 days, inclusive.

12. The method of claim 1 , further comprising administering a chemotherapeutic agent prior to the administration of the consecutive dose of cells.

13. The method of claim 1 , wherein the subject has been previously treated with a chemotherapeutic agent prior to administration of the first dose or prior to the administration of the consecutive dose.

14. The method of claim 12 , wherein the chemotherapeutic agent comprises cyclophosphamide or fludarabine.

15. The method of claim 12 , wherein the chemotherapeutic agent comprises cyclophosphamide and fludarabine.

16. The method of claim 13 , wherein the chemotherapeutic agent comprises cyclophosphamide or fludarabine.

17. The method of claim 13 , wherein the chemotherapeutic agent comprises cyclophosphamide and fludarabine.

18. The method of claim 1 , wherein the subject was treated with a chemotherapeutic agent at a time that was subsequent to the initiation of the administration of the first dose and prior to the initiation of the administration of the consecutive dose.

19. The method of claim 1 , wherein:
the first dose is a split dose, wherein the cells of the first dose are administered in a plurality of compositions, collectively comprising the cells of the first dose, over a period of no more than three days; or
the consecutive dose is a split dose, wherein the cells of the consecutive dose are administered in a plurality of compositions, collectively comprising the cells of the consecutive dose, over a period of no more than three days.

20. The method of claim 2 , further comprising administering a chemotherapeutic agent prior to the administration of the first dose of cells.

21. The method of claim 1 , wherein the hematologic malignancy is a leukemia or lymphoma.

22. The method of claim 1 , wherein the hematologic malignancy is non-Hodgkin lymphoma (NHL).

23. The method of claim 1 , wherein the number of CAR + cells administered in the first dose is at or about or no more than at or about 1×10 6 cells/kg the number of CAR + cells administered in the consecutive dose is at or about 3×10 6 cells/kg.

24. The method of claim 1 , further comprising administering to the subject one or more additional subsequent doses, wherein the first additional subsequent dose is administered at a time that is at least 14 days after the initiation of the administration of the consecutive dose.

25. The method of claim 1 , wherein
the consecutive dose is administered at a point in time at which:
(i) a clinical risk for neurotoxicity, cytokine-release syndrome (CRS), macrophage activation syndrome, or tumor lysis syndrome, is not present or has passed or has subsided following the administration of the first dose; (ii) a biochemical readout evidencing cytokine release syndrome (CRS), neurotoxicity, macrophage activation syndrome, or tumor lysis syndrome, is not present or has passed or has subsided following the administration of the first dose; (iii) a CRS-related outcome in the subject has reached a peak level and begun to decline following administration of the first dose; or (iv) a serum level of a factor indicative of CRS or neurotoxicity in the subject is no more than about 50 times the serum level of the factor in the subject immediately prior to the administration of the first dose; and

the subject does not exhibit a detectable adaptive host immune response specific for the CAR expressed by the cells of the first dose.

26. A method of treatment, comprising administering a consecutive dose of T cells expressing a chimeric antigen receptor (CAR) that binds to CD19 to a subject having a hematologic malignancy and having been previously administered a first dose of T cells expressing a CAR that binds to CD19, wherein:
(i) the first dose

Assignees

• Juno Therapeutics Inc

Inventors

• Gilbert Mark J

Classifications

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K2239/48

  Blood cells, e.g. leukemia or lymphoma · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title